AVP and autosomal dominant polycystic kidney disease: While Tolvaptan, an arginine vasopressin (AVP) V2 receptor antagonist, has been shown to slow the progression of disease and cysts growth in ADPKD [328], other medications targeting upregulated pathways were not as successful, even though studies in NPHP animal models were promising.